MX343517B - 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide. - Google Patents
2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide.Info
- Publication number
- MX343517B MX343517B MX2013010308A MX2013010308A MX343517B MX 343517 B MX343517 B MX 343517B MX 2013010308 A MX2013010308 A MX 2013010308A MX 2013010308 A MX2013010308 A MX 2013010308A MX 343517 B MX343517 B MX 343517B
- Authority
- MX
- Mexico
- Prior art keywords
- discoid lupus
- lupus erythematosus
- cutaneous lupus
- substituted pyrimidinediamines
- compounds
- Prior art date
Links
- 206010025135 lupus erythematosus Diseases 0.000 title abstract 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 title 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 title 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 208000011834 subacute cutaneous lupus erythematosus Diseases 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de las fórmulas I y II así como sales y composiciones farmacéuticas que los contienen, son útiles para tratar enfermedades y/o desordenes de la piel, tales como lupus cutáneo, por ejemplo lupus eritematoso cutáneo agudo, lupus eritematoso cutáneo subagudo, o lupus eritematoso discoide. En ciertas modalidades, los compuestos se proporcionan en composiciones tópicas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451531P | 2011-03-10 | 2011-03-10 | |
| PCT/US2012/028429 WO2012122452A1 (en) | 2011-03-10 | 2012-03-09 | 2,4 substituted pyrimidinediamines for use in discoid lupus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013010308A MX2013010308A (es) | 2013-12-02 |
| MX343517B true MX343517B (es) | 2016-11-07 |
Family
ID=45922810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010308A MX343517B (es) | 2011-03-10 | 2012-03-09 | 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8497279B2 (es) |
| EP (1) | EP2683385B1 (es) |
| JP (1) | JP6121917B2 (es) |
| KR (1) | KR101802011B1 (es) |
| CN (1) | CN103533938A (es) |
| AU (1) | AU2012225367B2 (es) |
| BR (1) | BR112013023052A2 (es) |
| CA (1) | CA2866460C (es) |
| CY (1) | CY1120860T1 (es) |
| DK (1) | DK2683385T3 (es) |
| EA (1) | EA030249B1 (es) |
| ES (1) | ES2686532T3 (es) |
| HR (1) | HRP20181286T1 (es) |
| HU (1) | HUE039486T2 (es) |
| LT (1) | LT2683385T (es) |
| MX (1) | MX343517B (es) |
| PL (1) | PL2683385T3 (es) |
| PT (1) | PT2683385T (es) |
| RS (1) | RS57672B1 (es) |
| SI (1) | SI2683385T1 (es) |
| SM (1) | SMT201800456T1 (es) |
| WO (1) | WO2012122452A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US9040061B2 (en) * | 2011-12-08 | 2015-05-26 | Rigel Pharmaceuticals, Inc. | Topical formulation for administering a compound |
| CA2884710A1 (en) | 2012-09-12 | 2014-03-20 | Rigel Pharmaceuticals, Inc. | Treatment for vitiligo |
| CN107805212B (zh) * | 2017-11-03 | 2021-08-20 | 宿迁德威化工股份有限公司 | 一种2-甲基-5-氨基苯磺酰胺的制备方法 |
| WO2021113410A1 (en) * | 2019-12-02 | 2021-06-10 | Ampersand Biopharmaceuticals, Inc. | Transdermal penetrant formulations for vitamins, minerals and supplements |
| CA3224094A1 (en) * | 2021-03-09 | 2022-09-15 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Use of tricyclic heteroaryl-containing compound |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US296006A (en) | 1884-04-01 | John hoefleb | ||
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| JPS6069037A (ja) | 1983-09-26 | 1985-04-19 | Sunstar Inc | エリテマト−デス治療用外用剤 |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| US5965154A (en) | 1998-03-17 | 1999-10-12 | Plc Holding, L.L.C. | Adhesive matrix type transdermal patch and method of manufacturing same |
| HRP20050089B1 (hr) | 2002-07-29 | 2015-06-19 | Rigel Pharmaceuticals | Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| AU2006254840B2 (en) | 2005-06-08 | 2012-08-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| US8013120B2 (en) | 2005-10-26 | 2011-09-06 | Stc.Unm | C-reactive protein and its use to treat systemic lupus erythematosus and related conditions |
| WO2007070872A1 (en) | 2005-12-15 | 2007-06-21 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
-
2012
- 2012-03-09 BR BR112013023052A patent/BR112013023052A2/pt not_active Application Discontinuation
- 2012-03-09 LT LTEP12711500.4T patent/LT2683385T/lt unknown
- 2012-03-09 KR KR1020137026550A patent/KR101802011B1/ko not_active Expired - Fee Related
- 2012-03-09 EA EA201391304A patent/EA030249B1/ru not_active IP Right Cessation
- 2012-03-09 CN CN201280021346.9A patent/CN103533938A/zh active Pending
- 2012-03-09 HU HUE12711500A patent/HUE039486T2/hu unknown
- 2012-03-09 RS RS20181046A patent/RS57672B1/sr unknown
- 2012-03-09 CA CA2866460A patent/CA2866460C/en not_active Expired - Fee Related
- 2012-03-09 SM SM20180456T patent/SMT201800456T1/it unknown
- 2012-03-09 PT PT12711500T patent/PT2683385T/pt unknown
- 2012-03-09 JP JP2013557894A patent/JP6121917B2/ja not_active Expired - Fee Related
- 2012-03-09 US US13/416,748 patent/US8497279B2/en not_active Expired - Fee Related
- 2012-03-09 PL PL12711500T patent/PL2683385T3/pl unknown
- 2012-03-09 MX MX2013010308A patent/MX343517B/es active IP Right Grant
- 2012-03-09 DK DK12711500.4T patent/DK2683385T3/en active
- 2012-03-09 EP EP12711500.4A patent/EP2683385B1/en active Active
- 2012-03-09 WO PCT/US2012/028429 patent/WO2012122452A1/en not_active Ceased
- 2012-03-09 ES ES12711500.4T patent/ES2686532T3/es active Active
- 2012-03-09 SI SI201231361T patent/SI2683385T1/sl unknown
- 2012-03-09 AU AU2012225367A patent/AU2012225367B2/en not_active Ceased
- 2012-03-09 HR HRP20181286TT patent/HRP20181286T1/hr unknown
-
2013
- 2013-05-30 US US13/906,083 patent/US20130274277A1/en not_active Abandoned
-
2018
- 2018-09-06 CY CY181100935T patent/CY1120860T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2866460A1 (en) | 2012-09-13 |
| PT2683385T (pt) | 2018-10-19 |
| JP2014507480A (ja) | 2014-03-27 |
| US20120232106A1 (en) | 2012-09-13 |
| CN103533938A (zh) | 2014-01-22 |
| EA030249B1 (ru) | 2018-07-31 |
| MX2013010308A (es) | 2013-12-02 |
| CA2866460C (en) | 2021-03-09 |
| BR112013023052A2 (pt) | 2017-07-25 |
| US8497279B2 (en) | 2013-07-30 |
| KR101802011B1 (ko) | 2017-11-27 |
| RS57672B1 (sr) | 2018-11-30 |
| HUE039486T2 (hu) | 2019-01-28 |
| HRP20181286T1 (hr) | 2018-10-05 |
| WO2012122452A1 (en) | 2012-09-13 |
| EA201391304A1 (ru) | 2014-05-30 |
| AU2012225367B2 (en) | 2017-05-25 |
| CY1120860T1 (el) | 2019-12-11 |
| SI2683385T1 (sl) | 2018-11-30 |
| PL2683385T3 (pl) | 2018-12-31 |
| ES2686532T3 (es) | 2018-10-18 |
| AU2012225367A1 (en) | 2013-10-24 |
| US20130274277A1 (en) | 2013-10-17 |
| EP2683385B1 (en) | 2018-06-06 |
| EP2683385A1 (en) | 2014-01-15 |
| DK2683385T3 (en) | 2018-09-17 |
| KR20140025377A (ko) | 2014-03-04 |
| JP6121917B2 (ja) | 2017-04-26 |
| LT2683385T (lt) | 2018-10-25 |
| SMT201800456T1 (it) | 2018-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20120099A7 (es) | Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos | |
| CL2017002650A1 (es) | Compuestos novedosos | |
| UY35827A (es) | Derivados de triazolopirazina como inhibidores de la proteína brd4 | |
| MX2015003140A (es) | Formulaciones de enzalutamida. | |
| DOP2015000241A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| CO6950476A2 (es) | Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| UY35427A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| UY35425A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| ECSP12011622A (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos | |
| UY35426A (es) | Compuestos y sus usos en la modulación de la hemoglobina | |
| UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
| PE20151023A1 (es) | Triazolopirazinas | |
| DOP2013000130A (es) | Compuestos de pirimidinona para uso en el tratamiento de las enfermedades o condiciones mediada por lp - pla2 | |
| ECSP14013215A (es) | Compuestos novedosos | |
| MX343517B (es) | 2,4 pirimidinadiaminas sustituidas para su uso en lupus discoide. | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| CR20140195A (es) | Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas | |
| NI201500050A (es) | Benzamidas | |
| GT201500069A (es) | Piridinonas bicìclicas novedosas | |
| DOP2015000170A (es) | Compuestos químicos | |
| GT201400288A (es) | "compuestos de fenoxietil piperidina" | |
| UY34169A (es) | ?compuestos heterociclicos microbiocidas,composiciones que los contienen, y métodos para controlar o prevenir la infestación de plantas | |
| CL2017000845A1 (es) | Inhibidores de gingipaina de lisina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |